Top

Published in:

01-09-2006 | Review

Regulatory T cells and innate immune regulation in tumor immunity

Author: Rong-Fu Wang

Published in: Seminars in Immunopathology | Issue 1/2006

Abstract

Innate and adaptive immunity play important roles in immunosurveillance and tumor destruction. However, increasing evidence suggests that tumor-infiltrating immune cells may have a dual function: inhibiting or promoting tumor growth and progression. Although regulatory T (Treg) cells induce immune tolerance by suppressing host immune responses against self- or nonself-antigens, thus playing critical roles in preventing autoimmune diseases, they might inhibit antitumor immunity and promote tumor growth. Recent studies demonstrate that elevated proportions of Treg cells are present in various types of cancers and suppress antitumor immunity. Furthermore, tumor-specific Treg cells can inhibit immune responses only when they are exposed to antigens presented by tumor cells. Therefore, Treg cells at tumor sites have detrimental effects on immunotherapy directed to cancer. This review will discuss recent progress in innate immunity, Treg cells, and their regulation through Toll-like receptor (TLR) signaling. It was generally thought that TLR-mediated recognition of specific structures of invading pathogens initiate innate and adaptive immune responses through dendritic cells. New evidence suggests that TLR signaling may directly regulate the suppressive function of Treg cells. Linking TLR signaling to the functional control of Treg cells opens intriguing opportunities to manipulate TLR signaling to control both innate and adaptive immunity against cancer.

Boon T, Van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729PubMedCrossRef

Wang RF, Rosenberg SA (1999) Human tumor antigens for cancer vaccine development. Immunol Rev 170:85–100PubMedCrossRef

Houghton AN, Gold JS, Blachere NE (2001) Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13:134–140PubMedCrossRef

Wang RF (2002) Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 188:65–80PubMedCrossRef

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915PubMedCrossRef

Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854PubMedCrossRef

Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78PubMedCrossRef

Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941–952PubMedCrossRef

Wang RF, Peng G, Wang HY (2006) Regulatory T cells and Toll-like receptors in tumor immunity. Semin Immunol 18:136–142PubMedCrossRef

10.

Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759PubMedCrossRef

11.

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148PubMedCrossRef

12.

Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511PubMedCrossRef

13.

Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21:685–711PubMedCrossRef

14.

Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213PubMedCrossRef

15.

Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538–18543PubMedCrossRef

16.

Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef

17.

Yu P, Rowley DA, Fu YX et al (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18(2):226–231PubMedCrossRef

18.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRef

19.

Clevers H (2004) At the crossroads of inflammation and cancer. Cell 118:671–674PubMedCrossRef

20.

Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263–266PubMedCrossRef

21.

Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296PubMedCrossRef

22.

Roncarolo MG, Levings MK (2000) The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol 12:676–683PubMedCrossRef

23.

Francois Bach J (2003) Regulatory T cells under scrutiny. Nat Rev Immunol 3:189–198PubMedCrossRef

24.

Weiner HL (2001) Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182:207–214PubMedCrossRef

25.

Sakaguchi S, Sakaguchi N, Shimizu J et al (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32PubMedCrossRef

26.

Wood KJ,Sakaguchi S (2003) Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3:199–210PubMedCrossRef

27.

Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor foxp3. Science 299:1057–1061PubMedCrossRef

28.

Khattri R, Cox T, Yasayko SA et al (2003) An essential role for Scurfin in CD4(+)CD25(+) T regulatory cells. Nat Immunol 4:337–342PubMedCrossRef

29.

Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol 4:330–336PubMedCrossRef

30.

Walker MR, Kasprowicz DJ, Gersuk VH et al (2003) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest 112:1437–1443PubMed

31.

Wang HY, Lee DA, Peng G et al (2004) Tumor-specific human CD4+ regulatory T cells and their ligands: implication for immunotherapy. Immunity 20:107–118PubMedCrossRef

32.

Fontenot JD, Rasmussen JP, Williams LM et al (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22:329–341PubMedCrossRef

33.

Wan YY, Flavell RA (2005) Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A 102:5126–5131PubMedCrossRef

34.

Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389–400PubMed

35.

Shevach EM (2000) Regulatory T cells in autoimmmunity. Annu Rev Immunol 18:423–449PubMedCrossRef

36.

Belkaid Y, Piccirillo CA, Mendez S et al (2002) CD4+CD25+ regulatory T cells control leishmania major persistence and immunity. Nature 420:502–507PubMedCrossRef

37.

Sakaguchi S (2004) Naturally arising CD4+ regulatory T Cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562PubMedCrossRef

38.

Berendt MJ, North RJ (1980) T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69–80PubMedCrossRef

39.

North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063–1074PubMedCrossRef

40.

Mukherji B, Guha A, Chakraborty NG et al (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961–1976PubMedCrossRef

41.

Chakraborty NG, Twardzik DR, Sivanandham M et al (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 145:2359–2364PubMed

42.

Woo EY, Chu CS, Goletz TJ et al (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4772PubMed

43.

Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761PubMed

44.

Viguier M, Lemaitre F, Verola O et al (2004) Foxp3 expressing CD4(+)CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444–1453PubMed

45.

Wang HY, Peng G, Guo Z et al (2005) Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 174:2661–2670PubMed

46.

Sarantopoulos S, Lu L, Cantor H (2004) Qa-1 restriction of CD8+ suppressor T cells. J Clin Invest 114:1218–1221PubMed

47.

Jiang H, Chess L (2004) An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 114:1198–1208PubMed

48.

Vlad G, Cortesini R, Suciu-Foca N (2005) License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 174:5907–5914PubMed

49.

Jiang H, Chess L (2000) The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu Rev Immunol 18:185–216PubMedCrossRef

50.

Hu D, Ikizawa K, Lu L et al (2004) Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 5:516–523PubMedCrossRef

51.

Cantor H (2004) Reviving suppression? Nat Immunol 5:347–349PubMedCrossRef

52.

Sakaguchi S, Sakaguchi N, Asano M et al (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164PubMed

53.

Hsieh CS, Liang Y, Tyznik AJ et al (2004) Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 21:267–277PubMedCrossRef

54.

Samy ET, Parker LA, Sharp CP et al (2005) Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med 202:771–781PubMedCrossRef

55.

Suffia IJ, Reckling SK, Piccirillo CA et al (2006) Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 203(3):777–788PubMedCrossRef

56.

Nishikawa H, Kato T, Tanida K et al (2003) CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A 100:10902–10906PubMedCrossRef

57.

Nishikawa H, Kato T, Tawara I et al (2005) Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med 201:681–686PubMedCrossRef

58.

Levings MK, Sangregorio R, Sartirana C et al (2002) Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 196:1335–1346PubMedCrossRef

59.

Dieckmann D, Bruett CH, Ploettner H et al (2002) Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells (corrected). J Exp Med 196:247–253PubMedCrossRef

60.

Jonuleit H, Schmitt E, Kakirman H et al (2002) Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 196:255–260PubMedCrossRef

61.

Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedCrossRef

62.

Jordan MS, Boesteanu A, Reed AJ et al (2001) Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2:301–306PubMedCrossRef

63.

Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4(+)CD25(+) regulatory T cells. J Immunol 171:5678–5682PubMed

64.

Apostolou I, Sarukhan A, Klein L et al (2002) Origin of regulatory T cells with known specificity for antigen. Nat Immunol 3:756–763PubMed

65.

Boonstra A, Asselin-Paturel C, Gilliet M et al (2003) Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 197:101–109PubMedCrossRef

66.

Apostolou I, Von Boehmer H (2004) In vivo instruction of suppressor commitment in naive T cells. J Exp Med 199:1401–1408PubMedCrossRef

67.

Kretschmer K, Apostolou I, Hawiger D et al (2005) Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6(12):1219–1227PubMedCrossRef

68.

Chen Y, Kuchroo VK, Inobe J et al (1994) Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237–1240PubMedCrossRef

69.

Jonuleit H, Schmitt E, Schuler G et al (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213–1222PubMedCrossRef

70.

Sundstedt A, O’Neill EJ, Nicolson KS et al (2003) Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol 170:1240–1248PubMed

71.

Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995PubMedCrossRef

72.

Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17:1–14PubMedCrossRef

73.

Heil F, Hemmi H, Hochrein H et al (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526–1529PubMedCrossRef

74.

Diebold SS, Kaisho T, Hemmi H et al (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531PubMedCrossRef

75.

Lund JM, Alexopoulou L, Sato A et al (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101:5598–5603PubMedCrossRef

76.

Jurk M, Heil F, Vollmer J et al (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3:499PubMedCrossRef

77.

Caramalho I, Lopes-Carvalho T, Ostler D et al (2003) Regulatory T Cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197:403–411PubMedCrossRef

78.

Hemmi H, Kaisho T, Takeuchi O et al (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196–200PubMedCrossRef

79.

Crozat K, Beutler B (2004) TLR7: a new sensor of viral infection. Proc Natl Acad Sci U S A 101:6835–6836PubMedCrossRef

80.

Takaoka A, Yanai H, Kondo S et al (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243–249PubMedCrossRef

81.

Honda K, Yanai H, Negishi H et al (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772–777PubMedCrossRef

82.

Honda K, Ohba Y, Yanai H et al (2005) Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction. Nature 434:1035–1040PubMedCrossRef

83.

Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801PubMedCrossRef

84.

Zheng SL, Augustsson-Balter K, Chang B et al (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 64:2918–2922PubMedCrossRef

85.

Sun J, Wiklund F, Zheng SL et al (2005) Sequence variants in Toll-like receptor gene cluster (TLR6–TLR1–TLR10) and prostate cancer risk. J Natl Cancer Inst 97:525–532PubMedCrossRef

86.

Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466PubMedCrossRef

87.

Luo JL, Maeda S, Hsu LC et al (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297–305PubMedCrossRef

88.

Maeda S, Kamata H, Luo JL et al (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977–990PubMedCrossRef

89.

Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124:823–835PubMedCrossRef

90.

Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211–5218PubMed

91.

Sutmuller RP, van Duivenvoorde LM, van Elsas A et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823–832PubMedCrossRef

92.

Attia P, Maker AV, Haworth LR et al (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28:582–592PubMedCrossRef

93.

Dannull J, Su Z, Rizzieri D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623–3633PubMedCrossRef

94.

Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036PubMedCrossRef

95.

Kubo T, Hatton RD, Oliver J et al (2004) Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 173:7249–7258PubMed

96.

Fehervari Z, Sakaguchi S (2004) Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol 16:1769–1780CrossRef

97.

Peng G, Guo Z, Kiniwa Y et al (2005) Toll-like receptor 8 mediated-reversal of CD4+ regulatory T cell function. Science 309:1380–1384PubMedCrossRef

98.

Crellin NK, Garcia RV, Hadisfar O et al (2005) Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol 175:8051–8059PubMed

99.

Netea MG, Sutmuller R, Hermann C et al (2004) Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 172:3712–3718PubMed

100.

Sutmuller RP, den Brok MH, Kramer M et al (2006) Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116:485–494PubMedCrossRef

Title: Regulatory T cells and innate immune regulation in tumor immunity
Author: Rong-Fu Wang
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1/2006
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-006-0022-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Regulatory T cells in human autoimmune diseases